The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Balan V.E.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Yureneva S.V.

Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

Smetnik V.P.

FGU Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova MZ SR RF, Moskva

Il'ina L.M.

Assotsiatsiia ginekologov-éndokrinologov, Moskva

Cardiovascular and metabolic disorders in menopause: the negative role of androgens in terms of evidence-based medicine

Authors:

Balan V.E., Yureneva S.V., Smetnik V.P., Il'ina L.M.

More about the authors

Journal: Russian Journal of Human Reproduction. 2012;(4): 100‑108

Read: 1224 times

Download PDF (RU)
Contact the author
Table of contents

CARDIOVASCULAR AND METABOLIC DISORDERS IN MENOPAUSE: THE NEGATIVE ROLE OF ANDROGENS IN TERMS OF EVIDENCE-BASED MEDICINE
CARDIOVASCULAR AND METABOLIC DISORDERS IN MENOPAUSE: THE NEGATIVE ROLE OF ANDROGENS IN TERMS OF EVIDENCE-BASED MEDICINE

To cite this article:

Balan VE, Yureneva SV, Smetnik VP, Il'ina LM. Cardiovascular and metabolic disorders in menopause: the negative role of androgens in terms of evidence-based medicine. Russian Journal of Human Reproduction. 2012;(4):100‑108. (In Russ.)

Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Hype­rtensive diso­rders of pregnancy as a risk factor for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(6):114-119
Scle­roatrophic lichen of the vulva: is it possible to solve the problem?. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):47-53
Abstract:

Authors:

Balan V.E.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Yureneva S.V.

Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

Smetnik V.P.

FGU Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova MZ SR RF, Moskva

Il'ina L.M.

Assotsiatsiia ginekologov-éndokrinologov, Moskva

Close metadata

References:

  1. Roger V.L. et al. On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease Stroke Statistics - 2011 update: a report from the American Heart Association. Circulation 2011; 123: 18-209.
  2. Carr M.C. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404-2411.
  3. Donato G.B., Fuchs S.C., Oppermann K., Bastos C., Spritzer P.M. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause 2006; 13: 280-285.
  4. Otsuki M., Kasayama S., Morita S. et al. Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women. Menopause 2007; 14: 404-407.
  5. Quyyumi A.A. Women and ischemic heart study: pathophysiologic implications from the Women's Ischemia Syndrome Evaluation (WISE) Study and future research steps. J Am Coll Cardiol 2006; 47: 3: Suppl: 66-71.
  6. Carey V.J., Walters E.E., Colditz G.A. et al. Body Fat Distribution and Risk Non-Insulin-dependent Diabetes Mellitus. The Nurses' Health Study. Am J Epidemiol 1997; 145: 614-619.
  7. Wenger N.K. Hypertension and other cardiovascular risk factors in women. Am J Hypertens 1995; 8: 94-99.
  8. The DECODE study group on behalf of the Europe an Diabetes Epidemiology Grour. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. The DECODE study group on behalf of the Europe an Diabetes Epidemiology Grour. Lancet 1999; 354: 9179: 617-621.
  9. Stone P.H., Thompson B., Anderson H.V. et al. Influence of race, sex and age on management of unstable angina and non-Q-wave myocardial infarction: the TIMI III registry. JAMA 1996; 275: 1104-1112.
  10. Fishman G.I., Chugh S.S., DiMarco J.P. et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society workshop. Circulation 2010; 122: 2335-2348.
  11. Rosamond W., Flegal K., Friday G. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: 69-171.
  12. Mosca L., Benjamin E.J., Berra K. et al. Effectiveness-based guidelines for the prevention of CVD in women-2011 update. A guideline from the American Heart Association. Circulation 2011; DOI:10.1161/CIR.0b013e31820faaf8. http://circ.ahajournals.org
  13. Daniel B., Arfan Ikram M., Elias-Smale S.E., Krestin G.P. et al. Calcification in Major Vessel Beds Relates to Vascular Brain Disease. Arterioscler Thromb Vasc Biol 2011;31: 12: 2982-9201.
  14. Lee M., Saver J.L., Chang B., Chang K.-H. et al. Presence of baseline prehypertension and risk of incident stroke. A metaanalysis. Neurology 2011; 77: 1330-1337.
  15. Notelovitz M. Androgen effects on bone and muscle. Fertil Steril 2002; 77: S34-S40.
  16. Bachmann G.A., Leiblum S.R. The impact of hormones on menopausal sexuality: a literature review. Menopause 2004; 11: 120-130.
  17. Tok E.C., Ertunc D., Oz U., Camdeviren H., Ozdemir G., Dilek S. The effect of circulating androgens on bone mineral density inpostmenopausal women. Maturitas 2004; 48: 235-242.
  18. Will M.A., Randolph J.F. The influence of reproductive hormones on brain function in the menopausal transition. Minerva Ginecol 2009; 61: 469-481.
  19. Liu Y., Ding J., Bush T.L. et al. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am J Epidemiol 2001; 154: 489-494.
  20. Torréns J.I., Sutton-Tyrrell K., Zhao X. et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: Study of Women's Health Across the Nation. Menopause 2009; 16: 2: 257-264.
  21. Woodis C.B., McLendon A.N., Muzyk A.J. Testosterone Supplementation for Hypoactive Sexual Desire Disorder in Women. Pharmacotherapy 2012; 32: 1: 38-53.
  22. Zumoff B., Strain G.W., Miller L.K., Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995; 80: 1429-1430.
  23. Davison S.L., Bell R., Donath S., Montalto J.G., Davis S.R. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90: 3847-3853.
  24. Magoffin D.A. Ovarian theca cell. Int J Biochem 2005; 37: 1344-1349.
  25. Labrie F., Martel C., Balser J. Wide distribution of serum DHEA and sex steroid levels in postmenopausal womenVrole of the ovary? Menopause 2011; 18: 30-43.
  26. Ethun K.F., Wood C.E., Parker C.R.Jr., Kaplan J.R., Chen H., Appt S.E. et al. Effect of ovarian aging on androgen biosynthesis in a cynomolgus macaque model. Climacteric 2012; 15: 82-92.
  27. Havelock J.C., Rainey W.E., Bradshaw K.D., Carr B.R. The post-menopausal ovary displays a unique pattern of steroidogenic enzyme expression. Hum Reprod 2006; 21: 309-317.
  28. Sowers M.F.R., Zheng H., McConnell D., Nan B. et al. Testosterone, sex hormone-binding globulin and the free androgen index among adult women: chronogical and ovarian aging. Hum Reprod 2009; 24: 9: 2276-2285.
  29. Barrett-Connor E., Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995; 311: 1193-1196.
  30. Guthrie J., Taffe J., Lehert P., Burger H., Dennerstein L. Association between hormonal changes at menopause and the risk of a coronary event: a longitudinal study. Menopause 2004; 11: 315-322.
  31. Sutton-Tyrrell K., Wildman R., Matthews K. et al. Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005; 111: 1242-1249.
  32. Santoro N., Torrens J., Crawford S. et al. Correlates of circulating androgens in mid-life women: the Study of Women's Health Across the Nation. J Clin Endocrinol Metab 2005; 90: 4836-4845.
  33. Janssen I., Powell L., Crawford S., Lasley B., Sutton-Tyrrell K. Menopause and the metabolic syndrome. Arch Int Med 2008; 168: 1568-1575.
  34. Wild R.A., Carmina E., Diamanti-Kandarakis E. et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95: 2038-2049.
  35. Fauser B.C.J.M., Tarlatzis B.C., Rebar R.W., Legro R.S., Balen A.H. et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2011; 97: 28-38.
  36. Jones G.L., Hall J.M., Balen A.H., Ledger W.L. Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. Hum Reprod Update 2008; 14: 15-25.
  37. Shaw L.J., Bairey Merz C.N., Azziz R., Stanczyk F.Z., Sopko G., Braunstein G.D. et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-1284.
  38. Zang H., Carlstrom K., Arner P., Hirschberg A.L. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil Steril 2006; 86: 136-144.
  39. Wierman M.E., Nappi R.E., Avis N. et al. Endocrine aspects of women's sexual function. J Sex Med 2010; 7: 561-585.
  40. Basson R., Brotto L.A., Petkau J., Labrie F. Role of androgens in women's sexual dysfunction. Menopause 2010; 17: 5: 962-997.
  41. American College of Obstetricians and Gynecologists (ACOG Female sexual dysfunction. Washington (DC): American College of Obstetricians and Gynecologists. ACOG 2011; 119.
  42. Labrie F., Archer D., Bouchard C. et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009; 16: 907-992.
  43. Panjari M., Davis S.R. DHEA for postmenopausal women: a review of the evidence. Maturitas 2010; 66: 172-179.
  44. Genazzani A.R., Pluchino N. DHEA therapy in postmenopausal women: the need to move forward beyond the lack of evidence. Climacteric 2010; 13: 314-316.
  45. Genazzani A.R., Stomati M., Valentino V. et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric 2011; 14: 661-668.
  46. Goncharov N.P., Katsiya G.V., Melikhova O.A., Smetnik V.P. Androgennyi defitsit u zhenshchin i vozmozhnosti ego gormonal'noi diagnostiki. Probl endokrinol 2011; 3: 31-36.
  47. Bachmanm G., Bancroft J., Braunstein G. et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77: 660-665.
  48. Wierman M.E., Basson R., Davis S.R. et al. Androgen therapy in women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 3694-3716.
  49. International Consultation on Sexual Medicine Organized under the auspices of the International Consultation on Urological Diseases (ICUD) and the International Society for Sexual Medicine (ISSM) July 10-13, 2009. ICSM2009_finalprogram_website.pdf
  50. Kloosterboe J. Historical milestones in the development of tibolone (Livial® ). Climacteric 2011; 14: 609-621.
  51. Nijland E.A., Weijmar Schultz W.C., Nathorst-Boös J. et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008; 5: 3: 646-656.
  52. Clarkson Th.B. Does tibolone exacerbate atherosclerosis? Eur Heart J 2006; 27: 635-637.
  53. Grinbaum M.L., de S. Ferreira J.A., Fernandes C.E., de Azevedo L.H. Evaluation of tibolone effect on arterial resistance in postmenopausal women. Climacteric 2003; 6: 151-158.
  54. Bots M.L. et al. The effect of tibolone and continuous combined conjugated equine estrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tibolone (OPAL) study. Eur Heart J 2006; 27: 746-755.
  55. Cummings S.R., Ettinger B., Delmas P.D., Kenemans P. et al. For the LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. NEJM 2008; 359: 21-32.
  56. Wassertheil-Smoller S., Hendrix S.L., Limacher M., Heiss G. Time to review all the evidence for hormone replacement therapy. JAMA 2003; 289: 2673-2684.
  57. Archer D.F., Thorneycroft I.H., Foegh M. et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716-727.
  58. Preston R.A. Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women. Climacteric 2009; 12: Suppl 1: 66-70.
  59. Seeger H., Wallwiener D., Mueck A.O.  Effects of drospirenone on cardiovascular markers in human aortic endothelial cells. Climacteric 2009; 12: 80-87.
  60. Knuuiti J., Kallokoski R., Janatuinen T. et al. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris Am J Cardiol 2007; 99: 1648-1652.
  61. Adasheva T.V., Zadionchenko V.S., Poryvkina O.N. i dr. Terapevticheskie aspekty primeneniya zamestitel'noi gormonal'noi terapii u patsientok s metabolicheskim sindromom v postmenopauze - vzglyad kardiologa. Kardiovask ter i prof 2009; 8: 49-55.
  62. Tanko L.B., Christiansen C. Effects of 17b-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Int Med 2005; 258: 544-553.
  63. Dinger J., Heinemann K. Berlin Center for Epidemiology and Health Research EURAS-HRT The Safety of Oral Hormone Replacement Therapy: Final Results from the EURAS-HRT Study. 13th World Congress on Menopause. Rome 2011.
  64. Thomas H.M., Bryce C.L., Ness R.B., Hess R. Dyspareunia is associated with decreased frequency of intercourse in the menopausal transition. Menopause 2011; 18: 2: 152-157.
  65. Gast M.J., Freedman M.A., Vieweg A.J. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 2009; 16: 2: 247-256.
  66. Gambacciani M., Rosano G., Cappagli B., Pepe A., Vitale C., Genazzani A.R. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011; 14: 18-24.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.